Komori
COSMOS Pharmaceutical (3349) · InitiativeReframed

Generating Earnings by Strengthening Initiatives Involving Value-Added Products

First written in FY2018. 3 of 10 entries say "Advanced", first in FY2019. Latest entry: FY2026.

10entries
9years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseReframedFY2024 – FY20252018: 120182019: 120192020: 120202021: 120212022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Profitability-Focused Sales and Product Mix ShiftA theme 42 companies write about · 0 as a headwind · 44 as a tailwind

COSMOS Pharmaceutical moved to the "Worse" side of this theme in 2024, 2 years before the typical company in this theme (2026).

The whole theme swung hardest in 2025: 3 of 26 companies on the "Worse" side.

1 other company's latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 42 companies compared. The sentences above are computed from all 42.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「The gross profit margin was 20.9%, down 0.2 percentage point from the previous consolidated fiscal year, as the Company limited the extent to which inflation-driven price increases were passed through in order to maintain its price advantage.」

    The Company prioritized low-price sales and limited the extent to which inflation-driven price increases were passed through, resulting in a decline in the gross profit margin from 21.1% to 20.9%.
  2. 2026-07-13OtherEarnings

    「Cost of sales 798,109 869,900 Gross profit 213,281 229,683」

    Gross profit increased from ¥213,281 million in the previous fiscal year to ¥229,683 million, but the earnings release contained no new policy explanation concerning value-added products or profit margins.
  3. FY2025ReframedAnnual report

    「The gross profit margin was 21.1%, up 1.6 percentage points from the previous consolidated fiscal year, as the Company passed through inflation-driven price increases while continuing negotiations to reduce procurement costs.」

    In addition to the previous focus on strengthening value-added products and low-price sales, the Company explicitly referred to passing through inflation-driven price increases, and the gross profit margin rose from 19.5% to 21.1%.
  4. FY2024ReframedAnnual report

    「The gross profit margin was 19.5%, down 0.8 percentage point from the previous consolidated fiscal year, as the Company continued negotiations to reduce procurement costs and endeavored to sell to customers at the lowest possible prices, even at the expense of profit, among other factors.」

    The focus shifted from the previous description of earning profits by strengthening value-added products to prioritizing lower procurement costs and low-price sales, and the gross profit margin declined to 19.5%.
  5. FY2023AdvancedAnnual report

    「The gross profit margin was 20.4%, up 0.4 percentage point from the previous consolidated fiscal year, as a result of efforts to sell products at the lowest possible prices while continuing negotiations to reduce procurement costs, among other factors.」

    As a result of continuing negotiations to reduce procurement costs and low-price sales, the gross profit margin rose from 20.0% in the previous fiscal year to 20.4%.
  6. FY2022RestatedAnnual report

    「The gross profit margin was 20.0%, unchanged from the previous consolidated fiscal year, as a result of efforts to sell products at the lowest possible prices while continuing negotiations to reduce procurement costs, among other factors.」

    The Company continued negotiations to reduce procurement costs and initiatives to sell at low prices, leaving the gross profit margin unchanged from the previous fiscal year at 20.0%.
  7. FY2021AdvancedAnnual report

    「The gross profit margin was 20.0%, up 0.3 percentage point from the previous consolidated fiscal year, as a result of continued efforts to strengthen initiatives for value-added products and negotiate lower procurement costs, among other factors.」

    As a result of continuing to strengthen initiatives for value-added products and negotiate lower procurement costs, the gross profit margin rose 0.3 percentage point from 19.7% in the previous fiscal year to 20.0%.
  8. FY2020RestatedAnnual report

    「The gross profit margin was 19.7%, down 0.2 percentage point from the previous consolidated fiscal year, despite continued efforts to strengthen initiatives for value-added products and negotiate lower procurement costs. This was due, among other factors, to the decision to leave tax-inclusive prices unchanged when the consumption tax was raised in October 2019 and the sharp increase in sales of food products, which have a relatively low gross margin, in the fourth quarter.」

    The Company continued initiatives for value-added products and lower procurement costs, but the gross profit margin declined to 19.7% due to unchanged tax-inclusive prices and increased food sales, among other factors.
  9. FY2019AdvancedAnnual report

    「The gross profit margin was 19.9%, up 0.1 percentage point from the previous consolidated fiscal year, as a result of continued efforts to strengthen initiatives for value-added products and negotiations to reduce procurement costs.」

    As a result of continuing to strengthen initiatives for value-added products and negotiate lower procurement costs, the gross profit margin rose 0.1 percentage point from 19.8% to 19.9%.
  10. FY2018First statedAnnual report

    「We sought to generate profit by strengthening initiatives for value-added products. However, following price-enhancement measures from the third quarter, the gross margin declined by 0.1 percentage point from the previous fiscal year to 19.8%.」

    This is the first thread to identify stronger initiatives for value-added products as a profit-generation measure pursued alongside low-price and price-enhancement strategies.
Moved together

"Further Growth Through Proactive Store Expansion" moved the same way as this thread, in the same document, in 3 of its 10 moves.

33322★12345
  1. ★This thread
  2. 1Further Growth Through Proactive Store Expansion3×
  3. 2New Store Openings and Expansion of the Store Network3×
  4. 3Continued Capital Investment in New Stores3×
  5. 4Achieving a Dominant Share in Western Japan2×
  6. 5No Performance-Linked or Share-Based Compensation Initially, Followed by a制度 Review2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for COSMOS Pharmaceutical yet. It last moved in the Earnings of 2026-07-13: "Other".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Generating Earnings by Strengthening Initiatives Involving Value-Added Products | COSMOS Pharmaceutical Corporation (3349) | Komori